Envision Pharma Group acquires artificial intelligence technology company OKRA.ai

Pivotal acquisition in Envision Pharma Group’s tech-enabled offerings provides clients with access to advanced AI to accelerate decision-making which optimizes their products’ path to market and ultimately supports the delivery of enhanced patient outcomes.

Envision Pharma Group acquires artificial intelligence technology company OKRA.ai

Feb 07, 2023
Envision Pharma Group acquires artificial intelligence technology company OKRA.ai Image

Envision Pharma Group (Envision), a leading global technology-enabled commercialization, integrated medical capabilities and solutions, and data analytics partner to the life sciences industry, announced today it has acquired OKRA.ai, an award-winning technology company active in the provision of artificial intelligence (AI) solutions with services across commercialization, real-world evidence and data analytics, medical, and pricing for the pharmaceutical and life sciences industry.

OKRA.ai’s AI products and solutions translate large clinical, scientific, and commercial data sets into actionable insights to empower decision-making and positive outcomes to clients in the life sciences industry.

“We are delighted to welcome OKRA.ai into the Envision family,” shares Meg Heim, CEO, Envision Pharma Group. “The acquisition of OKRA.ai marks an exciting milestone in Envision’s evolution as we continue to accelerate and deliver a compelling combination of technology-enabled capabilities and solutions to clients. The combination of Envision’s leading technology, capabilities, and solutions with OKRA.ai’s artificial intelligence expertise enables us to strengthen our offerings to clients across the product life cycle, but more importantly support patients in their journey to health and wellness.” 

Dr. Loubna Bouarfa, founder of OKRA.ai, will be joining Envision as a member of its Executive Leadership Team. Recently, Loubna won the prestigious Deloitte Fast 50 Women in Leadership Award and Forbes 50 Top Women in Tech. Loubna shares, “Today is a redefining moment for OKRA.ai. I am honored to be joining forces with Envision and to see the enormous opportunities for the growth of our combined expertise and solutions for clients in the life sciences industry. As part of Envision Pharma Group, we can accelerate our work to bring AI to the heart of decision-making across the life sciences industry. Our success will not only bring commercial benefit to clients, but lead to improved patient outcomes across the globe.” 

Based in the UK and Netherlands, OKRA.ai employs around 30 members of staff. The acquisition of OKRA.ai will bring the total number of Envision Pharma Group to 1400+ employees across four continents. 

Close

90TEN acquired by Envision Pharma Group

90TEN’s award-winning behavioral science-led communications group will help deliver a deeper and more diversified offering to Envision’s clients, while bringing significant geographical expansion opportunities for the London-based team

Envision Pharma Group ranked in top 10 of the fastest-growing UK companies in pharma

Coronavirus (COVID-19): a message from our CEO, David Thompson

90TEN acquired by Envision Pharma Group

Apr 08, 2020
90TEN acquired by Envision Pharma Group Image

Global healthcare communications consultancy 90TEN has been acquired by Envision Pharma Group – a global provider of evidence-based communication services and industry-leading technology solutions.

90TEN will retain its brand and service offering, bringing its insight-led behavioral science model Feel-Think-Do™ to a broad spectrum of Envision Pharma Group’s communications solutions. This partnership will enrich Envision Pharma Group’s global reach in medical affairs, which include its flagship technology, iEnvision®, together with strategic publications planning and delivery, medical strategy and communications, market access, and creative and digital solutions. In adding 90TEN’s strengths in behavioral science, creativity, and insight-driven communications, this acquisition will deliver an enhanced service offering to the Group’s global client base.

“We’re delighted to welcome an award-winning healthcare communications consultancy into the Envision Pharma Group family,” said David Thompson, CEO, Envision Pharma Group. “90TEN will add its expertise across new verticals for the group – in corporate communications and public relations, while extending Envision’s current footprint in patient engagement and medical communications with its behavioral science methodology. This move bolsters our industry-leading scientific communications capabilities, and enables us to strengthen our offering to clients across the product life cycle.”

“Today marks an exciting milestone in the evolution of 90TEN,” said Paul Tanner, Chairman, 90TEN. “Envision Pharma Group will provide global support to accelerate our plans to extend into more markets and reach more audiences. Both companies share the same values, which is reflected in the similarities between our passionate, ambitious, and collaborative teams who are dedicated to improving patient outcomes.”

Carole North, CEO, 90TEN added, “We’ve always said, if we partnered with another company it would have to be one that was the right strategic and cultural fit for 90TEN, celebrating everything that is 90TEN and the people who make it so successful. Envision Pharma Group embodies all of this and will allow us to retain our individuality, culture, and entrepreneurial spirit as we continue to deliver life-changing communications.”

90TEN will be managed from its London headquarters by the existing management team, including co-founders Paul Tanner and Carole North, and Managing Directors Peter Impey and Alison Doughty.

Based in London, 90TEN employs around 70 members of staff, and works with over half of the top 20 pharma companies in the world serving clients across Europe and North America. The acquisition of 90TEN will bring the total number of Envision Pharma Group employees to around 800 across 14 offices and four continents.

Close

Envision Pharma Group ranked in top 10 of the fastest-growing UK companies in pharma

Mar 25, 2020
Envision Pharma Group ranked in top 10 of the fastest-growing UK companies in pharma Image

Envision has achieved sixth position in the annual ranking of the UK’s Top 50 fastest-growing privately owned pharma businesses.

This marks the second successive year Envision has reached financial services firm Alantra’s Pharma Fast 50 list. Based on revenue growth, it recognizes the key British companies that are driving the healthcare sector forward.

Envision CEO David Thompson said, “We are very proud to be named once again in the Pharma Fast 50 list. To move from 19th place in 2019 to sixth in the rankings this year, speaks to all the hard work and dedication our superb team has put in as we continue to expand our technology-enabled scientific services for clients.”

Alantra Director and report author Tom Cowap comments in the publication, “These are dynamic and innovative businesses that continue to deliver remarkable growth and we are proud to highlight their success.”

Aside from additional recent industry awards that have been based on client campaigns and innovation within the sector, Envision as a business has previously enjoyed year-on-year accolades:

2019 – Positioned 19th in Alantra Pharma Fast 50, fastest-growing privately owned pharma business

2018 – Awarded at Super Sussex Growth event that highlighted top-performing, job-generating businesses

2017 – Named Best in Business for sustained sales growth as a mid-market company among the Top 20 fastest-growing businesses

To view the 2020 Pharma Fast 50 report, click here.

Close

Coronavirus (COVID-19): a message from our CEO, David Thompson

Mar 18, 2020
Coronavirus (COVID-19): a message from our CEO, David Thompson Image

With an eye toward everyone’s health and well-being, all Envision staff will work remotely from March 23 and until further notice.

The health of everyone, from our employees and clients to our collective families and communities, remains of paramount importance to all of us at Envision Pharma Group. As such, we have implemented a phased closure of our offices globally. From Monday, March 23, the whole of Envision Pharma Group will be decentralized and working remotely until further notice.

Please rest assured:

  • We will remain very much open and operational to support your ongoing and future needs
  • Members of your support team already successfully operate remotely through our flexible working framework, which we are now extending across our entire organization
  • You’ll continue to benefit from our experience in working with multidisciplinary teams, across multiple geographies and time zones, through video conferences and phone calls
  • You can expect minimal disruption to “business as usual” with our business continuity plan. Click here to learn more

I know you will join me in thanking and appreciating the tremendous efforts of our employees, healthcare workers, communities, and governments as we work in partnership to navigate this unfolding situation.

With an eye toward your own contingency planning, please remember your Envision team is here to support you, and we are ready to answer any questions you may have. Let us know how we can help by reaching out to your EPG team contact directly, or through our contact page.

Sincerely yours,

David

Close

Coronavirus (COVID-19): our business continuity plan ensures seamless delivery of client services

Envision Pharma Group kick off 2020 by scooping a triple win at the PM Society Awards

Envision Pharma Group evolves its Executive Leadership Team

Coronavirus (COVID-19): our business continuity plan ensures seamless delivery of client services

Mar 18, 2020
Coronavirus (COVID-19): our business continuity plan ensures seamless delivery of client services Image

With an eye toward everyone’s health and well-being, all Envision staff will work remotely from March 23 and until further notice.

Envision is prepared to deliver seamlessly on our service commitments – in any situation that threatens to impact “business as usual” – including Coronavirus (COVID-19).

Our clients choose us as a business partner, in part, because they believe in our business continuity plan. It has been in place since 2016 and we invest in it, test it, and update it regularly. It is compliant with ISO 27001:2013, and so are all of our key supply partners.

Our plan ensures:
• Maximum possible service levels are maintained
• We recover from interruptions as quickly as possible
• The likelihood and impact of interruptions are minimal

So, while – like many businesses – we are suspending non-essential travel, you can rest assured that our employees have access to the right tools and service providers to effectively work with your teams virtually, through video conferences and phone calls.

The health of our mutual employees and your business are of paramount importance to us. Thank you for your valued partnership as we work together to navigate through this unfolding situation.

Questions? Please reach out directly to your EPG team, or via our contact page.

Close

Envision Pharma Group kick off 2020 by scooping a triple win at the PM Society Awards

Jan 28, 2020
Envision Pharma Group kick off 2020 by scooping a triple win at the PM Society Awards Image

The PM Society Awards 2020 saw Envision pick up a gold award for Events and Exhibitions, along with two silver accolades for Interactive Communications and Innovations relating to its work in collaboration with Mundipharma.

Envision’s Mundipharma account team were joined by members of the pharma company on January 24 at The Grosvenor House in London to accept the outcome from the event judges, which even included a new category win for interactive communications.

Comments from the judges relating to the gold award noted, “It was a brave client who agreed not to show their data until delegates interacted with it, but it paid off.”

Multichannel Director at Envision Alex Watson added, “What a fantastic way for us to start the year with a triple win at the 2020 PM Society Awards. To make a real difference we believe you sometimes have to look at things from a different perspective.

“Congratulations to our exceptionally talented creative team who, in close partnership with Mundipharma and supported by woolley pau gyro, conceptualized and created this exemplar of MedComms lateral thinking that had a very real impact in getting this important message across.”

The PM Society Awards recognize creativity, impact, and innovation within communications activities in the pharmaceutical, biotechnology, and healthcare industries. The awards are unique among creative healthcare awards, in that they include categories judged by healthcare professionals – the targets of the work – as well as those judged by agency creatives and marketers.

Watson noted, “This is the second successive year that Envision has entered and won at the PM Society Awards. To have achieved this here two years in a row is testament to the talents and capabilities of our in-house team.”

Close

Envision Pharma Group evolves its Executive Leadership Team

Dec 05, 2019
Envision Pharma Group evolves its Executive Leadership Team Image

The Envision Pharma Group, a global technology-enabled scientific communications organization, announced today that David Thompson (right) who is currently its Chief Commercial Officer is to become the new Chief Executive Officer to coincide with the appointment of its current CEO, Brian Hepburn (left) – to the position of Executive Co-Chair for the Group. Both David and Brian will assume their new roles from January 1, 2020.

David said, “I am honored and truly excited to be taking on the role of CEO for the Envision Pharma Group. The Group has been immensely successful through its unique business model of combining strategic data-centric scientific services with best-in-class technology solutions, such as the gold standard publication planning tool, Datavision. I look forward to continuing that journey through organic growth with a focus on expanding our medical affairs value proposition via the iEnvision platform. We also plan to grow our footprint through strategic acquisitions for key adjacent services. Undoubtedly we have a unique opportunity to provide market-leading solutions (through a combination of world class services and technology enablement) to our client base – which will positively impact the effective and efficient dissemination of NCE data to HCPs, payors, and patients alike.”

David joined the organization as part of Envision’s acquisition of Alligent Biopharm Consulting LLC, in September of 2015. Since then David has been instrumental in expanding the Group’s multichannel medical communication capabilities, fully aligning with the medical strategy and data dissemination core competences of Envision. He will continue to drive Envision’s goal of being seen as a strategic partner of choice for the medical affairs function within our biopharmaceutical and medical device client base. David is a 24-year veteran of the pharma services industry, having spent 15 of those years in the United States. In this role he will be based out of our UK, Horsham offices.

Brian, founder CEO from 2001, will continue to provide strategic direction and management support for the Group. He will maintain an active role driving the culture and company ethos for the ever-expanding team – which to date has been instrumental in creating one of the world’s preeminent medical affairs-focused outsourced pharma technology and services organizations.

“I can think of no one better to take over the mantle of the CEO for the Group,” added Brian. “David has been with the organization for 4 years now and truly understands its DNA, which is often the biggest challenge for any incoming CEO. In addition, he brings an energy and ‘can-do’ attitude to the table which will ensure we continue to innovate and challenge the norm. This planned transition has been in the making for some time now and I look forward to working with him closely on this new phase of the journey for Envision.”

Close

World Diabetes Day 2019

Envision Pharma Group moves into vibrant new office space in the heart of Hammersmith, London

This year’s insightful Round Table helps identify 8 key trends that could influence the Medical Affairs industry

World Diabetes Day 2019

Nov 14, 2019
World Diabetes Day 2019 Image

Starting at the beginning, being able to spot the key warning signs of diabetes can be paramount for early diagnosis and treatment. However, half the people living with diabetes are doing so unknowingly. For this reason, the International Diabetes Federation wants to escalate the awareness of diabetes by educating the public. The hope is that this will increase recognition of warning signs and early treatment, and reduce the risks of long-term health complications. Diabetes requires constant management, ranging from daily medication and monitoring, to application of a healthy lifestyle – so having the support of family and friends is key.

This year the main theme for World Diabetes Day is family and diabetes, raising the awareness of the impact it can have on those around you.

Close

Envision Pharma Group moves into vibrant new office space in the heart of Hammersmith, London

Oct 28, 2019
Envision Pharma Group moves into vibrant new office space in the heart of Hammersmith, London Image

Envision has announced another office relocation for 2019, this time in West London. Situated just steps away from Hammersmith tube station, the new office will be home to an expanding group of talented Envision employees spanning disciplines in medical writing, HEOR and market access consulting, creative, account management and operations.

Global Business Unit Head Kristyn Morgan said, “With views over West London, a roof terrace and a dynamic working environment, we are thrilled to announce the opening of our newest office. 2019 has certainly been a year for Envision growth and office expansion, and we see 2020 looking no different. Our new Hammersmith location now has the appropriate space to accommodate our team, and the energy to attract incremental talent and skills to meet our pharmaceutical client’s evolving needs!”

This is the latest in a number of office announcements by Envision Pharma Group. Earlier this year Envision saw significant office expansion for both its Horsham and Wilmslow offices in the UK, and the relocation and expansion of two of its East Coast offices in the US. With an office opening now planned in Szeged, Hungary before 2020 – the rapid pace of growth for Envision continues.

Close

This year’s insightful Round Table helps identify 8 key trends that could influence the Medical Affairs industry

Oct 04, 2019
This year’s insightful Round Table helps identify 8 key trends that could influence the Medical Affairs industry Image

Every year, Envision Pharma Group holds a Medical Affairs (MA) Round Table meeting to bring together industry leaders and discuss current topics within MA. This year, approximately 15 attendees met in New York City to discuss industry best practices, understand common challenges that often arise – and have the opportunity to network with other industry leaders. The annual meeting helps to focus on, and discuss, important and valuable topics within our industry together. Past topics have included:

Past topic have included:

  • Global Alignment in Medical Affairs
  • Patient Engagement: Real-World Evidence
  • Insights Identification
  • Automation & Organizational Efficiencies
  • Medical Affairs Metrics
  • Thought-Leader Engagement
  • Demonstrating the Value of Medical Affairs
  • Maximizing Data Roll-Out

The outcomes from this year’s annual round table helped further Envision’s perspective surrounding the current landscape of our industry, and up and coming trends. Along with general industry research, stakeholder interviews, as well as the conversations had with this year’s attendees, the Envision team put together the Medical Affairs 5-year Landscape Analysis. This focuses on the major trends influencing MA and identifies the key findings. Additionally, the team was able to detect some of the major impacts each trend will have upon the industry, based on the information obtained from the research and stakeholder interviews.

Click here for a look at our interactive Landscape Analysis infographic inclusive of the 8 trends and the potential influence they could have on the Medical Affairs industry.

If you would like more information regarding the next Envision Pharma Group Medical Affairs Round Table, please get in touch: EPGRoundtable@Envisionpharmagroup.com

Close

Envision’s global reach expands further with the opening of an office in Szeged, Hungary

Envision Pharma Group are double award winners – winning Gold and Silver at the PM Society Digital Awards

Hot on the heels of announcing the opening of its new Warren, NJ office, Envision opens its doors to a new office in Fairfield, CT

Envision’s global reach expands further with the opening of an office in Szeged, Hungary

Oct 03, 2019
Envision’s global reach expands further with the opening of an office in Szeged, Hungary Image

Fuelled by continued growth in its technology solutions unit, Envision Pharma Group is opening a new office in Szeged, Hungary.

Peter Jankovics, Product Development, Technology Solutions said, “It is exciting that we can expand Envision’s presence in Central Europe by opening a modern and stylish office in the center of the beautiful city of Szeged, Hungary. This office will certainly help us to reach more people who could experience the rewarding work environment and culture Envision represents.”

Envision plans to open the doors by the end of year, and in the meantime continues to look for talented individuals interested in working in a global technology environment within the healthcare industry.

For more information on the technology opportunities we have available, contact opportunities-US@EnvisionPharmaGroup.com

Close

Envision Pharma Group are double award winners – winning Gold and Silver at the PM Society Digital Awards

Sep 23, 2019
Envision Pharma Group are double award winners – winning Gold and Silver at the PM Society Digital Awards Image

Envision has won gold and silver excellence awards for its work in collaboration with Mundipharma at the 10th anniversary of the PM Society Digital Awards.

The Mundipharma account team from Envision headed up to The Brewery, London on the 19th September to attend and await the outcome from the judges.

In recognition for its unique approach to digital creativity, the team scooped one Gold award for ‘Excellence in Congress, Meetings and Events’, along with a Silver for ‘Innovation – Creativity’.

Awards judge and Medical Director Joubert Gama said, “The team were really impressed with this entry, especially in terms of keeping with the theme of the congress which was sustainability. The technology was really well used and the insights gained from different customers were used to guide them for future materials.”

Multichannel Director at Envision Alex Watson added, “Envision Pharma Group are thrilled to have won both of these aspirational PM Society Digital Awards for our work in collaboration with Mundipharma.”

“Bringing physical and tangible interactions to the unbound value of digital communication channels is not only a recipe for communication success for both us and our clients, but more importantly also for healthcare professionals who see real value in having information personalised to their interests and delivered in engaging and memorable ways.”

Now in its 10th year, the PM Society Digital Awards strive to recognise digital effectiveness, creativity and innovation within the healthcare industry – highlighting programmes, tools and campaigns across a range of digital activities.”

There are 15 categories that are all judged over a two-stage process, with many of the judges working within the healthcare industry themselves, who are assisted by creative and digital experts.

Watson noted, “This is the first time Envision have entered the PM Society Digital Awards so to have achieved this accolade is testament to the talents and capabilities of our in-house team. Congratulations to all involved, and thank you Mundipharma for the opportunity.”

Close

Hot on the heels of announcing the opening of its new Warren, NJ office, Envision opens its doors to a new office in Fairfield, CT

Sep 17, 2019
Hot on the heels of announcing the opening of its new Warren, NJ office, Envision opens its doors to a new office in Fairfield, CT Image

Prompted by significant growth, the relocation from its Southport, CT office in August allows for continued company expansion amongst state of the art, modern surroundings. One of the many investments made at this new location is The Lab – an innovation space where teams and clients can immerse themselves and play with the latest technologies enhancing healthcare communications.

Envision Scientific Solutions Global Lead Susanne Clark said, “We’ve moved our Southport office location into this new custom remodeled office area. We are thrilled to be able to continue to grow together in our new space!

“This location provides greater opportunities for our teams to share ideas and collaborate together. The updates we’ve made have created a high tech, connected workspace that will benefit both our existing and future global medical affairs clients. We look forward to welcoming clients into our innovation Lab.”

With a new office opening in Warren, NJ , significant office expansion earlier this year in Horsham and Wilmslow, UK along with recent award successes – 2019 is proving to be an exciting time for the business, clients, and new talent in the medical affairs arena.

Close